List view / Grid view
18 December 2015 | By Victoria White
Variant says VAR 200 has potential for treating multiple indications associated with the damaging effects of cellular accumulation of cholesterol and lipids on the kidney, including focal segmental glomerulosclerosis...
6 November 2015 | By
This financial commitment is part of a projected investment of over $53 million in 2015 alone to support more than 380 new and ongoing studies around the world.
29 October 2015 | By Victoria White
If scientists can find an antagonist to block the CCR2 receptor, they may be able to control the progression of MS...
23 September 2015 | By Victoria White
C4XD expects to progress its type 2 diabetes and inflammation programmes into in vivo proof-of-principle testing in the next few months...
19 June 2015 | By SciFluor Life Sciences
SciFluor Life Sciences has announced that pre-clinical research demonstrating the potential effectiveness of its patented novel compound, SF0034, for treating epilepsy and preventing tinnitus was published in the peer-reviewed publication, The Journal of Neuroscience...
11 June 2015 | By Victoria White
The results of a study presented at EULAR 2015 showed that people with systemic sclerosis have a unique bacterial signature in their colon.
29 May 2015 | By Victoria White
Padlock Therapeutics has entered into an agreement to license intellectual property and a collection of assets targeted at PADs from GSK...
18 May 2015 | By Victoria White
Ablynx is set to collaborate with Genzyme to investigate Nanobodies against a target that plays an important role in multiple sclerosis (MS)...
9 April 2015 | By Victoria White
Pfizer has launched a new competitive grants programme to support research projects investigating the role of PCSK9 in health and cardiovascular disease...
13 February 2015 | By Effimune
Two major scientific articles validate Effimune’s drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system...
8 January 2015 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...
29 October 2014 | By Probiodrug AG
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has announced it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
Chemokines orchestrate leukocyte trafficking in the immune system, but unregulated or inappropriate chemokine activity plays a key role in many inflammatory, allergic and autoimmune diseases as well as metastatic tumour progression. The chemokine network is comprised of ~50 distinct ligands that specifically bind and activate a family of 20 G…
